Glenmark Pharma shares jumped 3% Friday after launching a Phase 3 trial of its lung cancer drug, Envafolimab, in India, with sites also being set up in Russia, Brazil and Mexico. A parallel study is already underway in China. The injectable therapy aims to make immunotherapy more accessible. Retail sentiment turned bullish on Stocktwits. Glenmark stock is up 35% year-to-date.